


Modelling the tumor microenvironment for therapeutic testing and target identification

Jonas Steenbrugge, PhD

Senior postdoctoral researcher



Laboratory of Biochemistry,
Department of Veterinary and Biosciences
Faculty of Veterinary Medicine,
Ghent University

Animal cancer models for clinical translation to the human cancer patient




Orthotopic tumor transplantation: triple-negative breast cancer (TNBC) as an example


5 mammary gland pairs





Intraductally injected mammary tumor cells recapitulate early and late TNBC stages



Growth kinetics and metastatic behavior of mouse TNBC cell line-derived primary tumors





	Mouse TNBC cell line	Mouse strain	Inoculated cell number	Time to reach humane endpoint (weeks)	Lung metastases
1	D2A1	BALB/C	50k	4	- (8/8 mice)
2	EMT6	BALB/C	50k	5	+ (5/8 mice)
3	4T1-cold	BALB/C	4k	5	++ (9/9 mice)
4	AT3	C57BL/6	200k	5	+ (4/8 mice)
5	4T1-hot	BALB/C	50k	6	++ (6/6 mice)
6	66CL4	BALB/C	200k	6	+ (6/10 mice)
7	PY230	C57BL/6	200k	6	- (8/8 mice)
8	MET1	FVB/N	12.5k	6	- (13/13 mice)
9	MVT1	FVB/N	12.5k	6	++ (11/11 mice)




Transcriptomic profiling of the mammary tumor microenvironment

Hallmarks of cancer




T-cell activation



Used for:

- Experimental therapeutic testing (e.g. c-MET inhibitor: *npj Breast Cancer*, 2021)
- Optimizing chemotherapeutic efficacy (e.g. cisplatin: *Oncoimmunology*, 2022)
- Identifying (immuno)therapeutic targets (2021-now)


Identifying immunotherapeutic targets in the mammary tumor microenvironment




Current focus is on:

- Cancer-associated fibroblasts
- Extracellular matrix components
- **Immunosuppressive myeloid cells (neutrophils)**


Chitinase 3-like 1 (CHI3L1) as candidate (immuno)therapeutic target in TNBC



Kim SH et al., World J Surg Oncol, 2007




He CH et al., Cell Rep, 2013




Ma B et al., Cancer Res, 2015


CHI3L1 deficiency reduces disease progression in the 4T1-based TNBC model



Caliper measurement







Ex vivo imaging (5 weeks p.i.)





Neutrophil-derived CHI3L1 stimulates immunosuppression in the 4T1-based TNBC model

CITE-seq (5 weeks p.i.)




Neutrophil-derived CHI3L1 stimulates immunosuppression in the 4T1-based TNBC model


CITE-seq (5 weeks p.i.)




PD-L1 on TAMs




PD-L2 on TAMs




PD-1 on CD8+ T-cells



PD-1 on memory CD4+ T-cells





CHI3L1 blockade alleviates anti-PD-(L)1 resistance in the 4T1-based TNBC model




Intraperitoneal (i.p.) treatments

Caliper measurement



Do you want to collaborate with us?



We are open for collaborations on:

- In vivo cancer models for **therapeutic testing**
- **Identifying and investigating targets of interest** in relevant cancer models
- Any other cancer-related subject that requires preclinical models

Jonas Steenbrugge, PhD

Senior postdoctoral researcher

Laboratory of Biochemistry

DEPARTMENT OF VETERINARY AND BIOSCIENCES (DI07)

E Jonas.Steenbrugge@ugent.be

T +32 9 264 73 56

National collaborations:



International collaborations:

